What is Somatostatin?

A 14-amino-acid hormone that switches off the release of several other hormones, including growth hormone and insulin.

Somatostatin in the library · · Human Trials · What are peptides?

46 registered trials · 1185 indexed papers · 2128 human / 1502 animal studies

From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.

What it is

A 14-amino-acid hormone that switches off the release of several other hormones, including growth hormone and insulin.

Type: Peptide hormone.

Definition (National Library of Medicine)

“A 14-amino acid peptide named for its ability to inhibit pituitary growth hormone release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. srif can also inhibit the release of thyroid-stimulating hormone; prolactin; insulin; and glucagon besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, srif-28 with a 14-amino acid extension at the N-terminal.”

  • MeSH: Somatostatin

Human research

The registered human trials and peer-reviewed human studies linked below are listed from ClinicalTrials.gov and PubMed. A study is linked only when Somatostatin is one of its interventions, or is named in the study title or subject headings.

Listing a study does not mean it showed a benefit, and it is not medical advice.

Registered human trials (46)

TrialPhaseStatusYearEnrolled
Terlipressin vs. Somatostatin in Cirrhotic Patients With Acute Variceal Bleeding and Renal Dysfunctionnot yet recruiting202664
Somatostatin Plus Clear Liquid Diet Versus Diverting Stoma in Patients With Rectal Cancer Undergoing Ultra-Low Anterior Resectionrecruiting202572
Effects of Terlipressin and Somatostatin on Portal Pressure in Patients Undergoing Living Donor Liver Transplantationrecruiting202550
Regional Lipolysis and Adipocyte Lipolysis Protein StimulationEARLY_Phase 1recruiting202424
Measuring Amino Acid and Glucose Metabolism in Healthy Volunteers and NAFLD Patients Using Total-body PETactive not recruiting202436
Direct Measurement of Proinsulin Clearance in HumansPhase 4withdrawn2022
The Effect of Lifestyle-induced Hepatic Steatosis on Glucagon-stimulated Amino Acid Turnovercompleted202120
Effect of Fasting Free Fatty Acids and Fasting Glucose on 1st and 2nd Phase Insulin SecretionPhase 4withdrawn2020
A Randomized Controlled Study on the Treatment of Cirrhosis Combined With Hypersplenismunknown2020368
Somatostatin in Living Donor Liver TransplantationPhase 4unknown201956
The Role of Somatostatin in the Hemodynamics of the Hepatic Circulation in Patients Undergoing Liver ResectionPhase 3unknown201940
Terlipressin on Effect of Renal Function in Cirrhotic Patients With Acute Gastrointestinal Hemorrhagecompleted20191682
Evaluation of Postoperative Ascites After Somatostatin Infusion Following Hepatectomy for Hepatocellular CarcinomaPhase 3completed2018179
Liver Glycogen and Hypoglycemia in HumansPhase 1active not recruiting201840
Terlipression Prevent Developing of Acute Kidney Injury During Upper-gastroentestinal BleedingPhase 4completed201854
Somatostatin Prevent Post-operation Pancreatic Fistula in Intermediate Risk Patients After PancreaticoduodenectomyPhase 4completed2018205
Prevention of Postoperative Pancreatic Fistula by SomatostatinPhase 3completed2017655
Metabolic Consequences of Gastrointestinal Surgeryterminated201781
The Treatment of Hepatocirrhosis and Portal Hypertensioncompleted2016108
In Vivo Assessment of Cellular Metabolism in HumansPhase 1completed201617
Treatment With Sandostatin in Patients With Castrate Resistance Prostate Cancer Showing Uptake of 68Ga-DOTATETPhase 1unknown201630
The Effect of Somatostatin for Treatment of Post Hepatectomy Liver Failure (PHLF)Phase 3unknown201520
Impact of Endogenous E2 on SSI and GH ReboundPhase 1completed201462
Effects of Terlipressin When Usual Somatostatin or Octreotide Dose Failsunknown20141320
Trial to Assess the Efficacy of Neuroprotective Drugs Administered Topically to Prevent or Arrest Diabetic RetinopathyPhase 2/Phase 3completed2013450
Application of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node DissectionPhase 4completed20132
Multi-center Clinical Study of Early Antibios of Severe Acute PancreatitisPhase 4unknown201260
Effects of Canagliflozin on C-peptide Clearance in Healthy VolunteersPhase 1completed201210
The Prophylactic Effect of Stilamin on Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitisunknown2011908
Effects of Somatostatin on Post-endoscopic Portal Hemodynamic in Cirrhotic Patients With Esophageal Gastric Varicesunknown2011126
Vasoactive Drugs in Real World PracticePhase 4completed2010150
Evaluation of Efficacy and Safety of Somatostatin Used as Inflow Modulator in Liver Transplantation.Phase 1completed201033
New Chemotherapy Regimen in the Treatment of Advanced Gallbladder CarcinomaPhase 3completed2009216
Peripheral Metabolic Effects of Somatostatincompleted20098
Identifying the Effect of Somatostatin Treatment in Early Postoperative Simple Small Bowel ObstructionPhase 4completed200944
Efficacy of Administration of Somatostatin in the Prevention of Post-endoscopic Retrograde Cholangiopancreatography (ERCP) PancreatitisPhase 3unknown2009510
Measurement of Glucose Metabolism in Humans Using Magnetic Resonance at 4 Tesla. Substudy: Hypoglycemia Unawarenesscompleted200719
Comparison of Terlipressin, Somatostatin, and Octreotide for Control of Variceal BleedingPhase 4completed20061034
Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up StudyPhase 3completed200678
EVL (Endoscopic Variceal Ligation) Plus Vasoconstrictor vs.Ligation Plus PPI( Proton Pump Inhibitor) in the Control of Acute Esophageal Variceal BleedingPhase 4completed2006118

Peer-reviewed studies (1185)

PaperAuthorsJournalYearType
Lanreotide, a Somatostatin Analogue, in Advanced Merkel Cell Carcinoma: A Prospective Single-Arm Phase II StudyCharles J et al.Cancer medicine2026Clinical Trial, Phase II
A long-acting octreotide analog formed by conjugation with a peptide linker modified with two fatty acidsYu YH et al.Frontiers in endocrinology2026Randomized Controlled Trial
Phase 1 Study of Paltusotine, a Novel Oral Once‑Daily, Nonpeptide Selective Somatostatin Receptor 2 Agonist, in Healthy Japanese AdultsOtsuka F et al.Clinical pharmacology in drug development2026Clinical Trial, Phase I
Reduced breakthrough symptom exacerbations in patients with biochemically controlled acromegaly switched from injected depot somatostatin receptor ligands to once-daily oral paltusotine in the PATHFNDR-1 clinical trialClemmons DR et al.Pituitary2026Randomized Controlled Trial
[(177)Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trialWalter T et al.Lancet (London, England)2026Randomized Controlled Trial
A three-year randomized, double-blind, placebo-controlled study of lanreotide in stage 2/3 autosomal dominant polycystic kidney diseaseJoly D et al.Kidney international2026Randomized Controlled Trial
Dosimetry Results from the Phase 1b/3 ACTION-1 Trial of [(225)Ac]Ac-DOTATATE (RYZ101) in Patients with Somatostatin Receptor-Expressing, Well-Differentiated GEP-NETsSgouros G et al.Journal of nuclear medicine : official publication, Society of Nuclear Medicine2026Randomized Controlled Trial
Effect of somatostatin receptor 2 antagonism on glucagon counterregulation during a hyperinsulinaemic euglycaemic-hypoglycaemic glucose clamp in adult men and women with long-standing type 1 diabetes: a randomised crossover phase 1 studyAbitbol A et al.Diabetologia2026Randomized Controlled Trial
First clinical demonstration of sustained insulin-like growth factor 1 elevation via oral somatostatin receptor 5 antagonism: a phase 1 trial of SCO-240Nishizaki H et al.European journal of endocrinology2026Randomized Controlled Trial
[Efficacy of octreotide LAR and lanreotide autogel in acromegaly assessed by SAGIT]Núñez-Martínez FJ et al.Revista medica del Instituto Mexicano del Seguro Social2026Observational Study
Real-World Observational Study of Somatostatin Analogs and Rescue Medication Usage for Neuroendocrine Tumors in CanadaRayson D et al.Neuroendocrinology2026Observational Study
Long-term efficacy and safety of peptide receptor radionuclide therapy in Japanese patients with unresectable neuroendocrine tumor: extension of the Japanese phase I and phase I/II studyKobayashi N et al.Annals of nuclear medicine2026Clinical Trial, Phase II
Ga-68-Edotreotide PET/CT SSTR Total Tumor Volume as a Predictor of Outcome in Patients With Metastatic Gastroenteropancreatic Neuroendocrine TumorsGallicchio R et al.Cancer control : journal of the Moffitt Cancer Center2026Observational Study
Malignancy Detection Rates of [(68)Ga]Ga-SSO120 PET/CT in Patients with Small Cell Lung Cancer and Large Cell Neuroendocrine Lung CancerChristensen TN et al.Journal of nuclear medicine : official publication, Society of Nuclear Medicine2026Clinical Trial, Phase II
Targeted β(-)-Particle Plus Conversion and Auger-Electron Therapy with (161)Tb-Labeled Somatostatin Receptor Antagonist DOTA-LM3: A Phase 0 StudyFricke JG et al.Journal of nuclear medicine : official publication, Society of Nuclear Medicine2026Randomized Controlled Trial
Rapid and Sustained Response of Biochemically Uncontrolled Acromegaly to Once-daily Oral Paltusotine TreatmentBiller BMK et al.The Journal of clinical endocrinology and metabolism2026Randomized Controlled Trial
[(177)Lu]Lu-DOTATATE for Recurrent Meningioma (LUMEN-1, EORTC-2334-BTG): Study Protocol for a Randomized Phase II TrialAlbert NL et al.Journal of nuclear medicine : official publication, Society of Nuclear Medicine2026Clinical Study
Effects of rebamipide quadruple therapy with gastrointestinal endoscopy adjuvant therapy on gastrointestinal hormones in patients with gastric ulcer bleedingJing J et al.Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology2025Randomized Controlled Trial
The effect of treatment with somatostatin analogs in children with neurofibromatosis type 1 and growth hormone excessKoch SS et al.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society2025Clinical Study
Rationale and design of the PAMSARC (pasireotide as maintenance treatment with monthly deep intramuscular injection in SSTR2/3/5-expressing synovial sarcoma and desmoplastic small round cell tumor) multicenter phase 2 trialHeilig CE et al.Cancer treatment and research communications2025Clinical Study
Tumor-infiltrating immune cells predict the response to somatostatin receptor ligands only in somatotropinomas naïve to medical therapyChiloiro S et al.Journal of neuroendocrinology2025Observational Study
Dosing patterns, healthcare resource utilization and costs among acromegaly patients who consistently use lanreotide and injectable octreotideQuock TP et al.Journal of comparative effectiveness research2025Observational Study
Somatostatin analogue continuation upon progression in patients with gastroenteropancreatic neuroendocrine tumour (SAUNA trial): a randomised controlled trial protocolChhajlani S et al.BMJ open2025Clinical Study
Safety and dosimetry of [(177)Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P studyGaze MN et al.European journal of nuclear medicine and molecular imaging2025Clinical Trial, Phase II
A Randomized clinical trial evaluating the impact on survival and quality of life of (177)Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)Capdevila J et al.BMC cancer2025Clinical Study
(177)Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I TrialHallqvist A et al.Journal of nuclear medicine : official publication, Society of Nuclear Medicine2025Clinical Trial, Phase I
Phase Ib/II study of Pembrolizumab with Lanreotide depot for advanced, progressive Gastroenteropancreatic neuroendocrine tumors (PLANET)Morse MA et al.Journal of neuroendocrinology2025Clinical Trial, Phase II
A phase II study of ramucirumab and somatostatin analog therapy in patients with advanced neuroendocrine tumorsPerez K et al.The oncologist2025Clinical Trial, Phase II
A retrospective observational clinical study of triple negative breast cancer cases treated with Di Bella Method: A preliminary dataDi Bella G et al.Neuro endocrinology letters2024Observational Study
Quantitative and qualitative assessment of a pituitary neuroendocrine tumor's T2-signal intensity in acromegaly - a call for unificationGodlewska-Nowak M et al.Frontiers in endocrinology2024Observational Study

More cited research

Conditions researched

Related compounds

FAQ

What is Somatostatin?

A 14-amino-acid hormone that switches off the release of several other hormones, including growth hormone and insulin.

How many registered human trials study Somatostatin?

The PeptideWhiz trial index lists 46 registered trials for Somatostatin, the most recent from 2026.

How much published research exists on Somatostatin?

The PeptideWhiz paper index links 1185 PubMed papers to Somatostatin; by study type, 2128 human and 1502 animal studies.

Which conditions is Somatostatin researched for?

Anti-aging & longevity, Anxiety and panic, Atherosclerosis, cardiovascular disease & high blood pressure, Chronic and systemic inflammation, Chronic pain: fibromyalgia & CRPS, Concussion, traumatic brain injury & stroke recovery, Delayed gastric emptying on GLP-1 medicines, Dementia, Alzheimer's & cognitive decline, Diabetic retinopathy and glaucoma, Eyes: macular degeneration & retinal health, Fat loss, obesity & body recomposition, Fatty liver & elevated liver enzymes, Gallbladder and gallstones, Gut: IBD (Crohn's, colitis), leaky gut, IBS & ulcers, Heart repair: after heart attack, heart failure & enlarged heart, High-demand jobs: military, fire, police, EMT (and combat-sport athletes), Hyperparathyroidism, Immune system (general), Insulin resistance, prediabetes & type 2 diabetes, Kidney protection (CKD, diabetic kidney, lupus kidney), Lung health, asthma & COPD, Lupus (SLE), Migraine, Muscle gain, sarcopenia & building muscle after 40, Neuropathy and CRPS, Osteoarthritis, cartilage loss & avoiding joint replacement, Pancreatitis (after the acute phase), Parkinson's disease, PCOS, Post-surgical inflammation and surgery recovery, Psoriasis and psoriatic arthritis, Rheumatoid arthritis, Sleep apnea (obstructive), Sleep problems (incl. insomnia on peptides), Thyroid problems, Varicose veins.

Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).

Reported dosing ranges from research